Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (16 ops.)
Latest filing published 14 May 2026 for Apellis Pharmaceuticals, Inc.. Read the official filing
Filing timeline
BuySaleMark Jeffrey DeLong
Insider track record
Disclosed buys
0
Disclosed sells
16
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Mark Jeffrey DeLong: trading record in brief
Mark Jeffrey DeLong is a declared insider of Apellis Pharmaceuticals, Inc. (senior executive), with filings sourced from SEC (Form 4). The record holds 44 filings, for trades running from 18 May 2021 to 14 May 2026.
Sales make up the whole of the open-market record (16 sales, €1.6M). Outside the open market, there are 14 share grants and 13 option exercises. In 2026 alone, the filings show no purchases and 4 sales.
The latest filing, published on 14 May 2026, reports a transaction in Apellis Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Mark Jeffrey DeLong
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations44 total
114,591 sharesCommon StockSEC:0001193125-26-224597:0
368 shares@ US$22.15370.3% of flowCommon StockSEC:0001492422-26-000083:0
36,606 shares0Common StockSEC:0001492422-26-000077:0
3,371 shares@ US$21.76542.7% of flowCommon StockSEC:0001492422-26-000059:0
1,334 shares@ US$19.79291.0% of flowCommon StockSEC:0001492422-26-000043:0
1,780 shares@ US$22.18721.4% of flowCommon StockSEC:0001492422-26-000030:0
363 shares@ US$28.53880.4% of flowCommon StockSEC:0001127602-25-004328:0
365 shares@ US$29.52360.5% of flowCommon StockSEC:0001127602-25-002373:0
1,396 shares@ US$30.42551.8% of flowCommon StockSEC:0001127602-25-001831:0
1,235 shares@ US$29.95821.6% of flowCommon StockSEC:0001127602-25-001616:0
28,508 shares0Common StockSEC:0001127602-25-001616:1
1,599 shares@ US$28.70212.0% of flowCommon StockSEC:0001127602-25-001185:0
5,201 shares@ US$13.852.9% of flowCommon StockSEC:0001127602-24-022070:0
9,913 shares@ US$56.9022.9% of flowCommon StockSEC:0001127602-24-010605:0
597 shares@ US$67.76691.7% of flowCommon StockSEC:0001127602-24-004711:0
367 shares@ US$64.13821.0% of flowCommon StockSEC:0001127602-24-002734:0
1,384 shares@ US$64.9963.7% of flowCommon StockSEC:0001127602-24-001931:0
16,963 shares0Common StockSEC:0001127602-24-001438:0
131 shares@ US$46.03620.3% of flowCommon StockSEC:0001127602-23-026187:0
5,280 shares0Common StockSEC:0000899243-23-005788:0
670 shares@ US$51.211.4% of flowCommon StockSEC:0001127602-23-005137:0
367 shares@ US$52.770.8% of flowCommon StockSEC:0001127602-23-002674:0
1,149 shares@ US$52.052.4% of flowCommon StockSEC:0001127602-23-002126:0
19,634 shares0Common StockSEC:0001127602-23-001492:0
196 shares@ US$58.000.5% of flowCommon StockSEC:0001127602-22-024301:0
25 of 44 declarations
